bromine

Oppenheimer initiated coverage of Albemarle Corporation (NYSE: ALB) at Outperform, with a $133 price target, which suggests about 17-percent upside from current levels. Analysts Colin Rush, Kristen Owen, Noah Kaye and Luis Amadeo said they expect Albemarle to benefit from its No. 1 position...